NEW YORK (AP) - Acura Pharmaceuticals Inc. will receive a $3 million payment from King Pharmaceuticals under a continuing licensing deal, the companies said Wednesday. Bristol, Tenn.-based King exercised its option to license a fourth immediate-release pain treatment using Palatine, Ill.-based Acura's technology, triggering the payment. The technology is used to make it more difficult for people to abuse the opioid analgesic pain products. The companies are already developing three other pain treatments under a deal signed in 2007. That deal allows King to exercise licensing options on all opioid analgesic pain products using Acura's Aversion technology in the U.S., Canada, and Mexico.